PNB Vesper has initiated six clinical trials in COVID-19, Ulcerative Colitis, Crohn's Disease, Colon Cancer, Pancreatic Cancer and Diabetes. Each of these indications is at a different stage of clinical trial.
This page summarises investigational research for scientific, clinical and partnering audiences. The molecules described are in development and this is not medical advice.
PNB-001 · Phase 1 · Healthy volunteers
Safety and dose-ranging in healthy volunteers
Completed
Participants
74 healthy subjects
Design
Single ascending dose, then multiple ascending dose
Dose range
25–1,500 mg (SAD); 50, 100, 200 mg (MAD, 14 days)
Purpose
Establish safety, tolerability and plasma exposure before patient studies.
Design
A single-ascending-dose (SAD) study in 42 subjects, followed by a multiple-ascending-dose (MAD) study at low, medium and high doses over 14 days in 32 subjects.
Results
The company reports PNB-001 was safe across the tested range and target plasma concentrations were reached. 30 of 32 subjects completed the MAD study, with 2 adverse reactions observed. Adverse events were mild, such as vomiting in one female subject; at a high dose, a 2.5-fold rise in the liver enzyme ALT was identified. A reduction in lipase was seen in the SAD study.
Limitations
Healthy volunteers only; results are summarised from company documents.
Phase 2 completed · Phase 3 approved, not enrolled
Design
Randomised, comparative
Population
Patients with moderate COVID-19
Published
medRxiv and Medwin Publishers
Purpose
Evaluate efficacy and safety of PNB-001 as an immune modulator in viral Lung Inflammation, where the cytokine storm (monitored by IL-6) drives severity.
Rationale
In a preclinical dengue-fever model, 10 mg/kg PNB-001 reduced the death rate by 70–80%, with a matching fall in IL-6.
Results
Hospitalisation rate and oxygen supplementation were reduced. The neutrophil-to-lymphocyte ratio (NLR) returned to the healthy range, and the inflammation markers ESR, CRP and IL-6 were reduced at two weeks. Clinical markers correlated with clinical outcome.
Next stage
The results were presented to India's drug regulator (DCGI) and a Phase 3 trial was approved, but patients were not enrolled owing to a lack of eligible patients.
Limitations
Quantitative outcomes are not given in the source summary; see the publications for full data.
50 or 100 mg PNB-001, three times daily, with mesalamine
Duration
28 days
Purpose
Test whether PNB-001 added to standard mesalamine therapy improves gut inflammation in Ulcerative Colitis.
Outcome measure
Response on the UC Disease Activity Index (UCDAI), which scores stool frequency, rectal bleeding, mucosal appearance and physician assessment.
Results
4 of 9 patients (44%) responded on mesalamine alone, compared with 5 of 9 (55%) with 50 mg and 8 of 9 (89%) with 100 mg PNB-001. The effect was dose-dependent; the 100 mg versus mesalamine comparison was reported as statistically significant (P = 0.05). No toxicity was found.
Next stage
A Phase 3 trial is listed as submitted in the pipeline table.
Limitations
Nine patients per arm and 28 days of treatment. The response analysis covers 27 of the 29 patients enrolled; P = 0.05 sits at the conventional significance threshold.
Responders on the UCDAI after 28 days
Add-on PNB-001 versus mesalamine alone
Responders on the UC Disease Activity Index after 28 days, by treatment arm
Explore PNB-001 as an add-on to mesalamine in Crohn's Disease.
Results
No reduction in disease activity was found compared with mesalamine alone. Pain relief was seen, and T cells followed the same trend as in Ulcerative Colitis.
Assess safety and early efficacy of the first irreversible CCK-C antagonist in pancreatic and Colorectal Cancer.
Basis
ICH preclinical toxicology and safety pharmacology completed; complete tumour-growth inhibition in pancreatic xenograft models.
Design
The protocol was approved for both cancer indications, with multiple ascending doses in patients for up to 56 days. The company considers this period sufficient for proof of efficacy toward market authorisation in India.
Assess safety and early efficacy of the first irreversible CCK-C antagonist in pancreatic and Colorectal Cancer.
Basis
ICH preclinical toxicology and safety pharmacology completed; complete tumour-growth inhibition in colon xenograft models.
Design
The protocol was approved for both cancer indications, with multiple ascending doses in patients for up to 56 days. The company considers this period sufficient for proof of efficacy toward market authorisation in India.